


Lynch syndrome found to be associated with more types of cancers

June 4 2018, by Bob Yirka



Micrograph showing tumour-infiltrating lymphocytes in colorectal carcinoma. H&E stain. Credit: Nephron/Wikipedia/CC BY-SA 3.0

A team of researchers at Memorial Sloan Kettering Cancer Center has found Lynch syndrome to be associated with more types of cancer than



previously thought. The group gave a presentation at this year's American Society of Clinical Oncology meeting outlining their findings.

Lynch syndrome is an inherited condition that results in a higher risk of developing certain types of cancer. Up until now, the elevated risk was thought to be restricted mostly to colon and endometrial cancers. But in this new effort, the researchers found evidence that suggests it can also be associated with other types of cancer, such as prostate, melanoma, ovarian germ cell, sarcoma and mesothelioma—and possibly many others.

Patients who develop endometrial or <u>colon cancer</u> are typically screened for Lynch syndrome, because if markers for it are present, they are likely to be more susceptible to developing it as well. Those who have been identified with it, including the initial patient, can then be offered options to reduce their risk factors or even to treat their tumors—the FDA has an approved therapy list for patients with Lynch syndrome.

The team was conducting a genetic study of tumor samples. They looked at 15,000 samples that included 50 different types of cancer. In particular, they were looking at those with high microsatellite instability (MSI-H) which not only increases the odds of a tumor spreading but of the patient having Lynch syndrome. As part of their analysis, the researchers found that approximately 16 percent of those patients with tumors who had high MSI-H also had Lynch Syndrome. Furthermore, they also found that approximately half of all the tumors they tested that came from patients with Lynch syndrome were not due to colon or endometrial cancers. This, the researchers noted, suggests that many more cancer patients need to be screened for Lynch syndrome than previously.

The researchers conclude that screening for Lynch syndrome accompanying other types of cancers can be done immediately. Doctors



need not wait for further results. Patients and their families can start benefiting right away.

More information: Pan-cancer microsatellite instability to predict for presence of Lynch syndrome,

abstracts.asco.org/214/AbstView 214 223301.html

Abstract

Background: The success of immunotherapy in microsatellite unstable (MSI-H) and/or DNA mismatch repair deficient (MMR-D) tumors has resulted in routine MSI-H/MMR-D testing in advanced solid tumors. Unlike colorectal (CRC) and endometrial cancer (EC), where this has long been undertaken, the characterization of Lynch syndrome (LS) across heterogeneous MSI-H/MMR-D tumors is unknown. Methods: Through a targeted NGS panel, MSI status was determined via MSIsensor. Scores of 50 cancers, 93.2% were MSS, 4.6% MSI-I, and 2.2% MSI-H. Germline mutations were identified in 0.3% (37/14,020), 1.9% (13/699), and 16.3% (53/326) in the MSS, MSI-I, and MSI-H groups, respectively (p-value

© 2018 Medical Xpress

Citation: Lynch syndrome found to be associated with more types of cancers (2018, June 4) retrieved 5 May 2024 from

https://medicalxpress.com/news/2018-06-lynch-syndrome-cancers.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.